Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 48.26 as of 2026-10-06T19:51:03.075Z.
Consensus retrieved: 2026-10-06T08:58:55.663Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:51:03.075Z.
Quote observation: 2026-10-06T19:50:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b9d80053686f16721d19c62710da14dda18ff2c6e5fba2adc15c1c35f0ac96a2
Forward PE Ratio (48.26) = Dated Quote Price ($23.99) / Consensus Forward EPS ($0.50)
FORWARD PE RATIO
48.26
SECTOR MEDIAN · HEALTHCARE
19.80
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+143.74%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$3.00B
Forward PE Ratio
48.26
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.00B | 48.26 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.00B | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.05B | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.85B | N/A |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.20B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.78B | 54.79 |
| AtriCure, Inc. (ATRC)vs › | $2.73B | N/A |
| Precigen, Inc. (PGEN)vs › | $2.71B | 44.29 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.30B | N/A |
Trailing P/E
115.1
reported TTM EPS
Forward P/E
48.3
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.50 implies +138.1% EPS growth vs the reported trailing $0.21.
At the dated quote price of $23.99, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.50 | $0.24 – $0.73 | 4 | 48.3x |
| 2027-12-31 | $1.33 | $1.16 – $1.60 | 4 | 18.1x |
| 2028-12-31 | $2.09 | $1.63 – $2.74 | 5 | 11.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
